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Dithranol was introduced into anti-psoriatic therapy 
in 1916, but the principle of its activity remains 
unkown with regard to the quantitative aspects of its 
efficacy e.g. in enzyme inhibition, D N A interaction 
and interference with lipid metabolism. In vitro ex-
periments have indicated that dithranol irreversibly 
inhibits glucose-6-phosphate-dehydrogenase (EC 
1.1.1.49) [10] and the incorporation of thymidine into 
D N A [6]. 
Compared with dithranol, there have been few 
investigations of dithranol triacetate and dithranol 
diacetate; dithranol triacetate has been introduced as 
an anti-psoriatic (Exolan) [5]). In vitro experiments 
using dithranol triacetate and dithranol diacetate with 
human serum have revealed that both molecules are 
hydrolytically and oxidatively degraded [12]. The dif-
ferent rates of absorption of differently labelled 
moieties of dithranol triacetate ( 1 4 C H 3 - C O , ^ - a n -
thracene) have been explained by (partial) hydrolysis 
in or on the skin [13], which suggests that this com-
pound has a pro-drug character. On the other hand, 
both dithranol acetates inhibit glucose-6-phosphate-
dehydrogenase [9]. In order to obtain a better 
comparison between dithranol and its acetates, we 
determined the influence of these compounds on the 
incorporation of thymidine into epidermal D N A . 
Dithranol and its tri- and diacetate were prepared 
as has previously been described [12]; dithranol and 
its triacetate were dissolved in acetone, and dithranol 
diacetate was dissolved in C H 2 C 1 2 (for concentrations, 
see Fig . 2). For each concentration (Fig. 2), five female 
mice (Charles River Wiga; 25 — 30 g) were shaved on 
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Fig. 1. Dithranol, its acetylesters and their degradation products 
the back and both sides; four mice were used for 
control experiments. In every case, 50 \il of the solu-
tion of dithranol and its esters (Fig. 1) was applied 
to 5 c m 2 of the skin. The animals were kept in single 
cages to prevent them licking each other, and they had 
free access to water and nutrition. After 5 h, 25 joCi 
3H-thymidine (20 C i / m M ; 0.9% NaCl ) was injected 
intraperitoneally, and exactly 1 h later, the mice were 
killed by cervical dislocation. The treated skin was 
excised, wrapped in aluminium foil and frozen in 
liquid N 2 . The epidermis and dermis were separated 
according to the methods of Mufson et al. [8] and 
Marrs and Voorhees [7], respectively. The frozen skin 
was dipped into water at 55° C for 1 min and then into 
an ice bath for a short time. The epidermis was then 
peeled from the dermis with a scalpel; about 15 mg 
epidermis was obtained from each mouse. Five-
millilitre syringes were loaded with a filter paper, 1 cm 
washed sand and 1.6 cm (about 0.75 g) 
hydroxylapatite ( D N A grade; Biogel HTP) , largely 
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Fig. 2. Decrease of thymidine incorporation into 
D N A with increasing concentrations of 
dithranol and its di- and triacetate. 
In brackets: 
mean values — cpm — and 
standard deviations for c = 0. 
Dithranol, O (640.3; 95.8); dithranol triacetate, 
x (528.4; 39.8); dithranol diacetate, + (504.7; 
55.3) 
in accordance with the procedure of du Vivier et al. 
In contrast to the findings of du Vivier et al. [2], 
the suspension of hydroxylapatite in the starting buf-
fer did not absorb D N A . Therefore, hydroxylapatite 
was suspended in 0.01 M elution buffer and boiled for 
a few seconds. The gel was stabilized in the syringe by 
washing twice with 5 ml starting buffer under slight 
pressure. 
Epidermis samples were homogenized with a 
borosilicate-glass tissue grinder in 2 ml lysing medium, 
and the suspension was carefully mixed with the 
hydroxylapatite with a Pasteur pipette. After 15 min, 
the R N A (Orcinol test [11]) and proteins (Folin-
Ciocalteu [14]) were eluted with 3 x 5 ml starting buffer 
under slight pressure, and the urea was then washed 
out with 4 x 5 ml 0.014 M elution buffer. The D N A 
was eluted with 0.48 M elution buffer; fractions 2 and 
3 (out of 4; 1.5 ml each) contained nearly the whole 
quantity of D N A (modified diphenylamine reagent 
[4]). Protein contamination was excluded by the rela-
tion: absorption 26o/adsorption 28o > 1.8 — adsorp-
t i o n ^ x 50 = D N A content [3]. 
As a variation of the method of du Vivier et al. 
[2], 8 ml instagel (Packard) was added to a solution 
containing 2 ml H 2 0 , 2 ml combined D N A fractions 
and 3 g urea. The mixture was converted to a stable 
1 The buffers were prepared according to the methods of du 
Vivier et al. [1, 2]. For the "starting buffer", 480.8 g (8 M) 
urea was dissolved to 11 in phosphate buffer p H 6.8. For the 
"lysing medium", 480.8 g (8 M) urea, 10 g sodium 
dodecylhydrogenosulfate (1%) and 292.2 mg ethylene-
diaminetetraacetate (EDTA; acid; 1 mM) were dissolved to 1 1 
in phosphate buffer p H 6.8. The phosphate buffers (0.010 M , 
0.014 M, 0.24 M , 0.48 M ; p H 6.8) were prepared from 
equimolar quantities of N a 2 H P 0 4 / 2 H 2 0 and N a H 2 P 0 4 / H 2 0 
gel by careful shaking. The number of counts per 
minute per 10 jug D N A was calculated. 
Metabolism of Dithranol Triacetate 
and Dithranol Diacetate 
One millilitre of 0.8% solution of dithranol triacetate 
in acetone and 1 ml 1.0% solution of dithranol 
diacetate in C H 2 C 1 2 were administered to the back 
and sides of one mouse each. The animals were killed 
after 6 h, the epidermis was homogenized in 5 ml start-
ing buffer, and the suspension was extracted three 
times with 5 ml C H 2 C 1 2 . The organic phase was dried 
over N a 2 S 0 4 , reduced to a small volume in vacuo 
and chromatographed on silica sheets 60 F 2 5 4 with 
toluene/acetone/glacial acetic acid (94/4/2 vol) or 
toluene/glacial acetic acid (80/20 vol). 
Figure 2 shows that dithranol is the strongest in-
hibitor of thymidine incorporation; the inhibition rate 
is related to the dose. Dithranol triacetate shows a 
weaker dose dependence; the inhibition rate is a little 
lower than that of dithranol at comparable doses 
(22 m M ; 2 m M ) . Dithranol diacetate, which is 
supposed to be more reactive against bionucleophiles 
because it is a phenylogous mixed anhydride, shows 
an inhibition rate which is comparable to that of 
dithranol triacetate. 
Even when high doses of the dithranol acetates 
were administered to the skin of one mouse each, 
dithranol triacetate was recovered in an unchanged 
form; however dithranol diacetate was to some extent 
oxidatively metabolized into chrysazin diacetate and 
1,8,1 \8'-tetraacetoxy-l 0,1O'-bisanthrone. Chrysazin 
diacetate and this bisanthrone also are produced by 
dithranol diacetate under non-enzymatic conditions. 
The hydrolysis of the dithranol acetates to dithranol, 
however, was not observed, which indicates that the 
inhibition of thymidine incorporation by these 
compounds is not caused by their conversion to 
dithranol. 
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